Stereotactic ablative radiotherapy (SABR) in operable early stage non-small cell lung cancer (NSCLC) patients: challenge to claim being undisputed gold standard.
Articles > Article ยท 2015
Authors: Deniz YALMAN, Ugur Selek
Annals of translational medicine, Journal Indexed in SCI Expanded, International, 2015, vol 3, pp 150-150
DOI: 10.3978/j.issn.2305-5839.2015.06.23
Summary
The standard treatment for operable, early stage non-small cell lung cancer (NSCLC) is surgical resection, usually lobectomy, with mediastinal lymph node sampling or dissection. However, significant surgical toxicity had been noted in these patients with 90-day mortality rates exceeding 30-day rates. There is also a risk of disease recurrence ranging from 6% to 10% per person-year during the first 4 years after surgery as stated by Lou et al. after an analysis of 1,300 patients who underwent surgery.